Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.
Publication
, Journal Article
Fixsen, E; Patel, J; Selim, MA; Kheterpal, M
Published in: Oncologist
March 2019
Checkpoint inhibitors such as pembrolizumab, an anti-PD-1 monoclonal antibody, are a promising new category of oncological therapeutics, associated with a higher risk of immune-related adverse events including dermatological, autoimmune and endocrine sequelae. Here, we present a case of a woman 76 years of age with stage IV lung adenocarcinoma who developed a severe and steroid-refractory lichenoid dermatitis associated with pruritus on pembrolizumab. This eruption resolved completely with a short course of oral cyclosporine. Cyclosporine is a promising and effective treatment option for checkpoint inhibitor-related severe cutaneous eruptions.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Oncologist
DOI
EISSN
1549-490X
Publication Date
March 2019
Volume
24
Issue
3
Start / End Page
e103 / e105
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- Lichenoid Eruptions
- Humans
- Female
- Dermatologic Agents
- Dermatitis
- Cyclosporine
- Antibodies, Monoclonal, Humanized
- Aged
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Fixsen, E., Patel, J., Selim, M. A., & Kheterpal, M. (2019). Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine. Oncologist, 24(3), e103–e105. https://doi.org/10.1634/theoncologist.2018-0531
Fixsen, Emma, Jigar Patel, Maria Angelica Selim, and Meenal Kheterpal. “Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.” Oncologist 24, no. 3 (March 2019): e103–5. https://doi.org/10.1634/theoncologist.2018-0531.
Fixsen E, Patel J, Selim MA, Kheterpal M. Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine. Oncologist. 2019 Mar;24(3):e103–5.
Fixsen, Emma, et al. “Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.” Oncologist, vol. 24, no. 3, Mar. 2019, pp. e103–05. Pubmed, doi:10.1634/theoncologist.2018-0531.
Fixsen E, Patel J, Selim MA, Kheterpal M. Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine. Oncologist. 2019 Mar;24(3):e103–e105.
Published In
Oncologist
DOI
EISSN
1549-490X
Publication Date
March 2019
Volume
24
Issue
3
Start / End Page
e103 / e105
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- Lichenoid Eruptions
- Humans
- Female
- Dermatologic Agents
- Dermatitis
- Cyclosporine
- Antibodies, Monoclonal, Humanized
- Aged
- 3211 Oncology and carcinogenesis